UK COVID-19 Diagnostics Market Growth Driven by Rising Demand for Rapid Testing Solutions
UK COVID-19 diagnostics market is driven by the increasing demand for accurate and rapid diagnostic testing, growing focus on infectious disease monitoring, and rising investments in healthcare testing infrastructure. Technologies such as PCR tests, antigen tests, serology tests, and rapid point-of-care testing solutions have witnessed significant adoption across laboratories, hospitals, diagnostic centers, and research institutes for efficient detection and management of COVID-19 infections. Additionally, increasing awareness regarding early disease diagnosis, advancements in diagnostic technologies, and strong government support for public health initiatives are further supporting the growth of the UK COVID-19 diagnostics market.
Browse the full report description of “UK COVID-19 Diagnostics Market Size, Share & Trends Analysis Report by Type (Instruments, Reagents & Kits, and Laboratory Testing Services), by Technology Type (PCR Test, Antigen Test, Serology Test, and Rapid/ PoC Test), by Sample Type (Oropharyngeal & Nasopharyngeal Swabs, Blood, Urine, Saliva, and Others), and by End-Users (Laboratories, Hospitals, Diagnostic Centers & Clinics, and Research Institutes) and Forecast, 2020-2026” at https://www.omrglobal.com/reports-category?search=UK+COVID-19+Diagnostics+Market
Source BioScience acquisition of Cambridge Clinical Laboratories is expected to strengthen the UK clinical diagnostics market in 2025
Source BioScience’s acquisition of Cambridge Clinical Laboratories in April 2025 is expected to strengthen the company’s position in the UK clinical diagnostics and molecular testing market. The acquisition supports the expansion of virology and infectious disease testing capabilities, which are witnessing growing demand due to the increasing prevalence of infectious diseases and the rising need for advanced molecular diagnostics. The integration of expanded laboratory infrastructure and specialized testing services is expected to improve diagnostic efficiency, increase testing capacity, and support the adoption of precision diagnostic solutions across healthcare facilities in the UK.
RDi acquisition of Inicio Health is expected to support digital diagnostics expansion in 2025
RDi’s acquisition of Inicio Health in April 2025 is expected to enhance its capabilities in digital diagnostics, home testing, and healthcare interoperability solutions within the UK diagnostics market. The increasing adoption of decentralized healthcare services and remote patient monitoring is driving demand for integrated digital diagnostic platforms. The acquisition is expected to accelerate the development of connected healthcare ecosystems, improve accessibility to diagnostic services, and strengthen home-based testing solutions, which are becoming increasingly important for efficient disease management and patient convenience.
Una Health partnership with Credo Diagnostics for VitaSIRO solo™ platform is expected to enhance respiratory diagnostics capabilities in 2025
Una Health’s partnership with Credo Diagnostics in December 2025 is expected to strengthen the UK respiratory diagnostics market through the expansion of the VitaSIRO solo™ multiplex PCR platform. The platform supports rapid detection of COVID-19, influenza, and RSV, addressing the growing need for accurate and fast respiratory infection testing. Increasing seasonal respiratory disease cases and the demand for rapid molecular diagnostics are key factors supporting the adoption of multiplex PCR technologies. The partnership is expected to improve testing efficiency and support timely clinical decision-making in healthcare settings.
Una Health agreement for VitaPCR™ rapid molecular testing platform is expected to support point-of-care diagnostics growth in 2025
Una Health’s strategic agreement with Credo Diagnostics in July 2025 to distribute the VitaPCR™ rapid molecular testing platform is expected to contribute to the growth of the UK point-of-care diagnostics market. The platform enables rapid detection of SARS-CoV-2, Influenza A/B, and RSV in point-of-care environments, supporting faster diagnosis and treatment decisions. The increasing demand for decentralized diagnostic solutions, combined with the growing emphasis on rapid infectious disease detection, is expected to drive adoption of portable molecular testing technologies across clinics, hospitals, and emergency care settings.
About OMR Global
OMR Global is a market intelligence and strategic consulting firm specializing in growth advisory, competitive intelligence, and AI-enabled business research across global B2B industries.
The company supports enterprises, investors, and technology providers with actionable insights for market entry, investment analysis, procurement strategy, commercialization, and business expansion. OMR Global combines industry expertise, primary research, analytics, and digital intelligence tools to help organizations navigate evolving market landscapes and identify growth opportunities.
OMR Digital Offerings
- Pulse Intelligence Platform – AI-powered market intelligence suite designed to deliver analyst-grade insights faster and more efficiently. Built on 12+ years of research expertise and enhanced with AI-driven analytics, Pulse helps organizations transform large volumes of market and company data into actionable intelligence within hours instead of weeks. Trusted by Fortune 500 enterprises, global investment banks, strategy consultancies, and PE & VC firms, Pulse supports strategic decision-making across investment evaluation, competitive benchmarking, AI readiness, and market positioning.
Other Offerings
- Lead Generation – Verified B2B prospect data, ICP targeting, and intent-based sales intelligence
- RFx Support – End-to-end RFP, RFI, and RFQ support with vendor benchmarking and evaluation frameworks
OMR Global delivers data-driven intelligence solutions designed to support strategic decision-making, operational efficiency, and long-term business growth.
To find out more, visit www.omrglobal.com
Contact:
Mr. Anurag Tiwari
305-308, Commerce House, Janjeerwala Square,
Indore, Madhya Pradesh 452001
India
+91-780-304-0404